Gyre Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2017 | — | $13.8M | $14.5M |
| Jun 2017 | — | $30.3M | $32.4M |
| Sep 2017 | — | $24.9M | $11.0M |
| Dec 2017 | — | $30.8M | $14.5M |
| Mar 2018 | — | $142.9M | $126.6M |
| Jun 2018 | — | $137.0M | $46.5M |
| Sep 2018 | — | $130.0M | $36.0M |
| Dec 2018 | — | $119.9M | $31.2M |
| Mar 2019 | — | $105.8M | $25.0M |
| Jun 2019 | — | $93.1M | $17.3M |
| Sep 2019 | — | $81.3M | $23.0M |
| Dec 2019 | — | $68.3M | $15.4M |
| Mar 2020 | — | $97.5M | $70.4M |
| Jun 2020 | — | $109.0M | $59.3M |
| Sep 2020 | — | $94.1M | $24.9M |
| Dec 2020 | — | $76.1M | $30.4M |
| Mar 2021 | — | $104.1M | $83.0M |
| Jun 2021 | — | $85.2M | $73.6M |
| Sep 2021 | — | $60.7M | $59.2M |
| Dec 2021 | — | $41.1M | $44.3M |
| Mar 2022 | — | $27.1M | $34.8M |
| Jun 2022 | — | $79.1M | $75.4M |
| Sep 2022 | — | $29.4M | $23.1M |
| Dec 2022 | — | $42.5M | $25.2M |
| Mar 2023 | — | $-26.0M | $8.1M |
| Jun 2023 | — | $-28.3M | $6.9M |
| Sep 2023 | — | $3.5M | $2.2M |
| Dec 2023 | — | $-15.8M | $33.5M |
| Mar 2024 | — | $56.6M | $29.8M |
| Jun 2024 | — | $60.4M | $16.1M |
| Sep 2024 | — | $63.2M | $15.9M |
| Dec 2024 | — | $63.3M | $11.8M |
| Mar 2025 | — | $68.1M | $15.0M |
| Jun 2025 | — | $92.0M | $36.5M |
| Sep 2025 | — | $101.9M | $40.4M |
| Dec 2025 | — | $62.5M | $49.2M |
| Mar 2026 | — | $101.3M | $37.5M |
| Jun 2026 | — | $107.9M | $43.3M |